Oppenheimer Reaffirms Outperform Rating for Odyssey Therapeutics (NASDAQ:ODTX)

Odyssey Therapeutics (NASDAQ:ODTX)‘s stock had its “outperform” rating reaffirmed by research analysts at Oppenheimer in a note issued to investors on Thursday,Benzinga reports. They presently have a $40.00 price target on the stock. Oppenheimer’s price target would indicate a potential upside of 117.04% from the company’s current price.

Several other research firms also recently commented on ODTX. Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a report on Wednesday, June 3rd. TD Cowen began coverage on Odyssey Therapeutics in a report on Tuesday, June 2nd. They set a “buy” rating for the company. Cantor Fitzgerald began coverage on Odyssey Therapeutics in a report on Tuesday, June 2nd. They set an “overweight” rating for the company. Wall Street Zen upgraded Odyssey Therapeutics to a “hold” rating in a report on Saturday, May 16th. Finally, JPMorgan Chase & Co. began coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “overweight” rating and a $26.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Odyssey Therapeutics Stock Performance

Shares of NASDAQ ODTX traded down $0.05 during midday trading on Thursday, hitting $18.43. 158,404 shares of the stock traded hands, compared to its average volume of 323,311. Odyssey Therapeutics has a one year low of $15.35 and a one year high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last released its quarterly earnings data on Wednesday, June 17th. The company reported $999.00 EPS for the quarter, beating the consensus estimate of ($1.31) by $1,000.31.

Insider Activity at Odyssey Therapeutics

In related news, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the completion of the transaction, the insider directly owned 1,831,383 shares in the company, valued at approximately $32,964,894. This represents a 43.54% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dimension Capital Ii, L.P. bought 1,111,111 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $19,999,998.00. Following the transaction, the director owned 3,333,516 shares of the company’s stock, valued at $60,003,288. The trade was a 50.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 4,183,777 shares of company stock valued at $75,319,986 over the last 90 days.